Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LBX1 antisense RNA 1 (LBX1-AS1)
- Target
- LBX1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
LBX1 antisense RNA 1 (LBX1-AS1) is a long non-coding RNA (lncRNA) transcribed in proximity to the LBX1 locus, head-to-head with the LBX1 gene. LBX1-AS1 regulates gene expression by sponging microRNAs such as miR-182-5p, leading to upregulation of tumor suppressor genes like FOXO3 and inhibition of cell proliferation and invasion in oral squamous cell carcinoma. It also impacts epigenetic regulation via altered CTCF binding, affecting DNA methylation and the expression of neighboring genes. LBX1-AS1 is associated with disease processes including cancer and glaucoma, serving as a potential biomarker for disease progression and prognosis. LBX1-AS1 is not considered a classical druggable target but is important in regulatory RNA biology and disease association studies.
- Other names
- FLJ41350MUSELBX1 antisense RNA 1 (head to head)LBX1-AS1
02
Mechanism of action
Acts as a competitive endogenous RNA (ceRNA) inhibiting miR-182-5p and upregulating FOXO3, a tumor suppressor gene. May affect gene expression through modulation of CTCF binding and DNA methylation.
03
Biological functions
Gene expression regulationTumor suppression (demonstrated in oral squamous cell carcinoma)miRNA sponging (miR-182-5p)
04
Disease associations
Cancer (oral squamous cell carcinoma)Primary open-angle glaucoma (association with gene polymorphisms)Potential regulatory roles in other conditions linked to LBX1, e.g., adolescent idiopathic scoliosis, but LBX1-AS1’s specific contribution is less established
05
Safety considerations
No direct safety concerns are described, as LBX1-AS1 is not a direct target of any approved therapiesTherapeutic modulation of noncoding RNAs may have off-target regulatory effects
06
Biomarkers
LBX1-AS1 expression can serve as a biomarker for tumor suppression activity and prognosis in oral squamous cell carcinomaPotentially a biomarker for association studies in glaucoma
Beyond the preview
Go deeper on LBX1 antisense RNA 1 (LBX1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBX1 antisense RNA 1 (LBX1-AS1).